WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its Virtual Control Groups (VCG) initiative with Sanofi. The companies are working together to reduce animal usage by replacing selected control group animals with selected matched virtual control animals developed using retrospective datasets.

马萨诸塞州威尔明顿。-（商业新闻短讯）--查尔斯河实验室国际公司（纽约证券交易所：CRL）今天宣布与赛诺菲启动其虚拟控制小组（VCG）计划。这些公司正在共同努力，通过使用回顾性数据集开发的选定匹配的虚拟对照动物替代选定的对照组动物来减少动物的使用。

The VCG collaboration is a project guided by Charles River’s Alternative Methods Advancement Project (AMAP), an initiative focused on reducing the use of animals in research..

VCG合作是由Charles River替代方法推进项目（AMAP）指导的一个项目，该项目旨在减少研究中动物的使用。。

“Charles River is uniquely positioned to combine the science of toxicology with the power of machine learning to drive greater use of VCGs for nonclinical research across the industry,” said Shannon Parisotto, Corporate Executive Vice President, Global Discovery & Safety Assessment, Charles River. “We have an unmatched breadth of data, providing a powerful database of study parameters.

Charles River全球发现与安全评估公司执行副总裁Shannon Parisotto表示：“Charles River具有独特的优势，可以将毒理学与机器学习的力量结合起来，推动整个行业更多地将VCG用于非临床研究。”。“我们拥有无与伦比的数据广度，提供了强大的研究参数数据库。

By leveraging this historical information, we are able to reduce control group animals and provide clients with meaningful study results.”.

通过利用这些历史信息，我们能够减少对照组动物，并为客户提供有意义的研究结果。”。

A VCG is a data-driven, digital creation based on robust historical study data, parameters, and complex statistical methodology. VCGs are an established practice in some clinical trials, however the application to preclinical research is new. Charles River is partnering with internal and external stakeholders, including regulators and leaders from the biopharmaceutical industry to advance this research.

VCG是基于可靠的历史研究数据、参数和复杂的统计方法的数据驱动的数字创建。VCG在一些临床试验中是一种既定做法，但在临床前研究中的应用是新的。Charles River正在与内部和外部利益相关者合作，包括监管机构和生物制药行业的领导者，以推进这项研究。

Charles River and Sanofi are collaborating to pilot VCGs in nonclinical toxicology programs and explore their use..

查尔斯·里弗（Charles River）和赛诺菲（Sanofi）正在合作在非临床毒理学项目中试验VCG，并探索其用途。。

“We are proud to work with Charles River on this important initiative,” said Philippe Detilleux, Global Head of Preclinical Safety, Sanofi. “We have an incredible opportunity to advance sustainable science by reducing our reliance on animal models, and VCGs are one way in which we are utilizing technology to make progress in this area.”.

赛诺菲临床前安全全球负责人菲利普·德蒂勒克斯（PhilippeDetilleux）表示：“我们很自豪能与查尔斯·里弗（CharlesRiver）合作完成这项重要举措。”。“通过减少对动物模型的依赖，我们有一个难以置信的机会来推进可持续科学，而VCG是我们利用技术在这一领域取得进展的一种方式。”。

As more studies are designed using VCGs, with a myriad of industry partners, increased levels of data will support their refinement, making VCGs more suitable replacements for animals in research.

随着越来越多的研究使用VCG进行设计，并有无数的行业合作伙伴，数据水平的提高将支持其改进，使VCG更适合替代研究中的动物。

About the Alternative Methods Advancement Project (AMAP)

关于替代方法改进项目（AMAP）

The Alternative Methods Advancement Project (AMAP) is a Charles River initiative dedicated to developing alternatives to reduce the use of animals in testing. As we enter the next frontier of drug development, AMAP will facilitate strategic and purposeful investing to lead the way toward a future where more patients receive needed treatments and medicines safely, swiftly, and successfully.

替代方法改进项目（AMAP）是查尔斯河倡议，致力于开发替代方法，以减少测试中动物的使用。随着我们进入药物开发的下一个前沿，AMAP将促进战略性和有目的的投资，以引领更多患者安全，快速，成功地接受所需治疗和药物的未来。

In keeping with our commitment to the 4Rs, we are dedicated to pursuing scientific and technological innovations to explore new and exciting ways we can further reduce the use of animals in testing. The guidance of AMAP will help us align our investments, partnerships, product and service initiatives, and advocacy efforts as we focus on our goal of investing $300 million over the next five years to further enhance this critical mission and drive industry-wide adoption of alternatives..

根据我们对4R的承诺，我们致力于追求科学技术创新，探索新的令人兴奋的方法，以进一步减少动物在测试中的使用。AMAP的指导将帮助我们调整我们的投资、合作伙伴关系、产品和服务计划以及宣传工作，因为我们专注于在未来五年投资3亿美元的目标，以进一步加强这一关键任务，并推动全行业采用替代方案。。

About Charles River

关于查尔斯河

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

查尔斯河提供重要的产品和服务，以帮助制药和生物技术公司、政府机构和全球领先的学术机构加速其研究和药物开发工作。我们敬业的员工专注于为客户提供他们所需要的，以改进和加速为需要的患者发现、早期开发和安全制造新疗法。

To learn more about our unique portfolio and breadth of services, visit www.criver.com..

要了解更多有关我们独特的产品组合和服务范围的信息，请访问www.criver.com。。